Benjamin Hohl is CFO at Enliven Therapeutics, Inc. (ELVN). They have made 1 open-market trade across 1 company since 2023, most recently 2026-09-17.
CIK 0001882764
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ELVN | 38,000 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-09-21 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELVN | SELL · 10b5-1 | 2026-09-17 | 2026-09-21 | $50.35 | $303K | -4.3% | — | — |
| ELVN | SELL · 10b5-1 | 2026-08-17 | 2026-08-19 | $58.58 | $353K | -1.4% | -15.9% | — |
| ELVN | SELL · 10b5-1 | 2026-07-17 | 2026-07-21 | $52.64 | $317K | +3.0% | +11.0% | — |
| ELVN | SELL · 10b5-1 | 2026-06-17 | 2026-06-22 | $43.80 | $264K | +10.3% | +17.2% | +8.3% |
| ELVN | SELL | 2026-03-06 | 2026-03-10 | $29.58 | $296K | -0.8% | +52.8% | +12.7% |
| ELVN | SELL · 10b5-1 | 2025-09-29 | 2025-10-01 | $20.40 | $66K | +3.8% | +17.5% | -22.0% |
| ELVN | SELL · 10b5-1 | 2025-08-27 | 2025-08-29 | $20.63 | $134K | -1.7% | +0.1% | +6.6% |
| ELVN | SELL · 10b5-1 | 2025-07-28 | 2025-07-30 | $20.46 | $132K | -4.7% | +6.7% | +13.4% |
| ELVN | SELL · 10b5-1 | 2025-07-10 | 2025-07-14 | $22.66 | $23K | -5.7% | -14.2% | -11.2% |
| ELVN | SELL · 10b5-1 | 2025-06-27 | 2025-07-01 | $20.89 | $132K | +14.8% | -6.1% | +1.3% |
| ELVN | SELL · 10b5-1 | 2025-06-13 | 2025-06-17 | $22.55 | $68K | -8.1% | +6.9% | -15.3% |
| ELVN | SELL · 10b5-1 | 2025-05-27 | 2025-05-29 | $16.18 | $53K | +21.2% | +12.1% | +15.5% |
| ELVN | SELL · 10b5-1 | 2025-04-28 | 2025-04-30 | $18.68 | $120K | +0.2% | -6.4% | +5.7% |
| ELVN | SELL · 10b5-1 | 2025-03-27 | 2025-03-31 | $21.33 | $139K | -23.1% | -2.3% | +3.5% |
| ELVN | SELL · 10b5-1 | 2025-03-24 | 2025-03-26 | $22.50 | $23K | -13.9% | -12.2% | +2.0% |
| ELVN | SELL · 10b5-1 | 2025-02-27 | 2025-03-03 | $20.41 | $133K | +4.8% | +2.6% | -1.1% |
| ELVN | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $22.52 | $23K | -2.6% | -8.1% | -15.5% |
| ELVN | SELL · 10b5-1 | 2025-01-27 | 2025-01-29 | $21.59 | $140K | +2.0% | -1.4% | -11.7% |
| ELVN | SELL · 10b5-1 | 2025-01-03 | 2025-01-07 | $25.04 | $25K | -6.1% | -4.1% | -23.7% |
| ELVN | SELL · 10b5-1 | 2024-12-27 | 2024-12-31 | $22.19 | $169K | -10.3% | -6.7% | -13.7% |
| ELVN | SELL · 10b5-1 | 2024-11-27 | 2024-12-02 | $24.89 | $131K | -4.4% | -0.7% | -18.5% |
| ELVN | SELL · 10b5-1 | 2024-10-28 | 2024-10-30 | $28.55 | $178K | -3.7% | -15.1% | -26.7% |
| ELVN | SELL · 10b5-1 | 2024-10-18 | 2024-10-22 | $30.00 | $24K | -3.8% | -11.6% | -23.4% |
| ELVN | SELL · 10b5-1 | 2024-10-04 | 2024-10-08 | $27.51 | $597K | +4.1% | +4.1% | -13.6% |
| ELVN | SELL · 10b5-1 | 2024-10-01 | 2024-10-03 | $27.54 | $14K | +6.5% | +5.9% | -8.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.